LICOCHALCONE A AS A POTENTIAL MULTI-TARGET DRUG AGAINST COGNITIVE DYSFUNCTION IN LPS-INDUCED NEUROINFLAMMATION MICE MODEL

• Marina Carrasco,
• Leila Driouech,
• Mireia Millet,
• Jordi Olloquequi,
• Ester Verdaguer,
• Jesus Mariano Ureña,
• Carme Auladell,
• Antoni Camins,
• Miren Ettcheto

Affiliations

Marina Carrasco

Universitat de Barcelona, Department Of Pharmacology, Toxicology And Therapeutic Chemistry, Faculty Of Pharmacy And Food Science, Barcelona, Spain; Instituto de Salud Carlos III, Biomedical Research Networking Center In Neurodegenerative Diseases (ciberned), Barcelona, Spain; Universitat de Barcelona, Institute Of Neuroscience, Barcelona, Spain; Universitat Rovira i Virgili, Department Of Biochemistry And Biotechnology, Faculty Of Medicine And Health Science, Reus, Spain; Institute of Health Pere Virgili-IISPV, Nutrition And Metabolic Disorders Research Group, Reus, Spain

Leila Driouech

Universitat de Barcelona, Department Of Pharmacology, Toxicology And Therapeutic Chemistry, Faculty Of Pharmacy And Food Science, Barcelona, Spain

Mireia Millet

Universitat de Barcelona, Department Of Pharmacology, Toxicology And Therapeutic Chemistry, Faculty Of Pharmacy And Food Science, Barcelona, Spain; Universitat de Barcelona, Institute Of Neuroscience, Barcelona, Spain

Jordi Olloquequi

Barcelona University. Pharmacy Faculty, Biochemistry And Physiology, Barcelona, Chile; Universidad Autónoma de Chile, Institute Of Biomedical Sciences, Faculty Of Health Sciences, Talca, Chile

Ester Verdaguer

Instituto de Salud Carlos III, Biomedical Research Networking Center In Neurodegenerative Diseases (ciberned), Barcelona, Spain; Universitat de Barcelona, Institute Of Neuroscience, Barcelona, Spain; Universitat de Barcelona, Department Of Cellular Biology, Physiology And Immunology, Barcelona, Spain

Jesus Mariano Ureña

Instituto de Salud Carlos III, Biomedical Research Networking Center In Neurodegenerative Diseases (ciberned), Barcelona, Spain; Universitat de Barcelona, Department Of Cellular Biology, Physiology And Immunology, Barcelona, Spain

Carme Auladell

Instituto de Salud Carlos III, Biomedical Research Networking Center In Neurodegenerative Diseases (ciberned), Barcelona, Spain; Universitat de Barcelona, Institute Of Neuroscience, Barcelona, Spain; Universitat de Barcelona, Department Of Cellular Biology, Physiology And Immunology, Barcelona, Spain

Antoni Camins

Universitat de Barcelona, Department Of Pharmacology, Toxicology And Therapeutic Chemistry, Faculty Of Pharmacy And Food Science, Barcelona, Spain; Instituto de Salud Carlos III, Biomedical Research Networking Center In Neurodegenerative Diseases (ciberned), Barcelona, Spain; Universitat de Barcelona, Institute Of Neuroscience, Barcelona, Spain; Institute of Health Pere Virgili-IISPV, Nutrition And Metabolic Disorders Research Group, Reus, Spain

Miren Ettcheto

Universitat de Barcelona, Department Of Pharmacology, Toxicology And Therapeutic Chemistry, Faculty Of Pharmacy And Food Science, Barcelona, Spain; Instituto de Salud Carlos III, Biomedical Research Networking Center In Neurodegenerative Diseases (ciberned), Barcelona, Spain; Universitat de Barcelona, Institute Of Neuroscience, Barcelona, Spain; Institute of Health Pere Virgili-IISPV, Nutrition And Metabolic Disorders Research Group, Reus, Spain